180 related articles for article (PubMed ID: 9624468)
21. Susceptibility of Escherichia coli isolates with TEM-1 beta-lactamase to combinations of BRL42715, tazobactam or clavulanate with piperacillin or amoxycillin .
Livermore DM; Seetulsingh P
J Antimicrob Chemother; 1991 Jun; 27(6):761-7. PubMed ID: 1669013
[TBL] [Abstract][Full Text] [Related]
22. Effect of the inhibitor-resistant M69V substitution on the structures and populations of trans-enamine beta-lactamase intermediates.
Totir MA; Padayatti PS; Helfand MS; Carey MP; Bonomo RA; Carey PR; van den Akker F
Biochemistry; 2006 Oct; 45(39):11895-904. PubMed ID: 17002290
[TBL] [Abstract][Full Text] [Related]
23. Clinical isolates of Escherichia coli producing multiple TEM mutants resistant to beta-lactamase inhibitors.
Sirot D; Chanal C; Henquell C; Labia R; Sirot J; Cluzel R
J Antimicrob Chemother; 1994 Jun; 33(6):1117-26. PubMed ID: 7928805
[TBL] [Abstract][Full Text] [Related]
24. A complex mutant of TEM-1 beta-lactamase with mutations encountered in both IRT-4 and extended-spectrum TEM-15, produced by an Escherichia coli clinical isolate.
Sirot D; Recule C; Chaibi EB; Bret L; Croize J; Chanal-Claris C; Labia R; Sirot J
Antimicrob Agents Chemother; 1997 Jun; 41(6):1322-5. PubMed ID: 9174192
[TBL] [Abstract][Full Text] [Related]
25. [Resistance to amoxicillin and amoxicillin-clavulanic acid combination of 231 clinical strains of Escherichia coli, isolated in 1992 at the Cochin Hospital].
Bémer-Melchior P; Gilly L; Jugroot-Klotz K; Brun T; Névot P; Paul G
Pathol Biol (Paris); 1995 Nov; 43(9):760-5. PubMed ID: 8746097
[TBL] [Abstract][Full Text] [Related]
26. Mutant TEM beta-lactamase producing resistance to ceftazidime, ampicillins, and beta-lactamase inhibitors.
Vakulenko S; Golemi D
Antimicrob Agents Chemother; 2002 Mar; 46(3):646-53. PubMed ID: 11850243
[TBL] [Abstract][Full Text] [Related]
27. Elucidating the role of Trp105 in the KPC-2 β-lactamase.
Papp-Wallace KM; Taracila M; Wallace CJ; Hujer KM; Bethel CR; Hornick JM; Bonomo RA
Protein Sci; 2010 Sep; 19(9):1714-27. PubMed ID: 20662006
[TBL] [Abstract][Full Text] [Related]
28. Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
Papp-Wallace KM; Taracila M; Hornick JM; Hujer AM; Hujer KM; Distler AM; Endimiani A; Bonomo RA
Antimicrob Agents Chemother; 2010 Jul; 54(7):2867-77. PubMed ID: 20421396
[TBL] [Abstract][Full Text] [Related]
29. Kinetic analysis of an inhibitor-resistant variant of the OHIO-1 beta-lactamase, an SHV-family class A enzyme.
Lin S; Thomas M; Shlaes DM; Rudin SD; Knox JR; Anderson V; Bonomo RA
Biochem J; 1998 Jul; 333 ( Pt 2)(Pt 2):395-400. PubMed ID: 9735103
[TBL] [Abstract][Full Text] [Related]
30. Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases.
Gatermann S; Marre R
Infection; 1991; 19(2):106-9. PubMed ID: 1646771
[TBL] [Abstract][Full Text] [Related]
31. Antimicrobial susceptibilities of Campylobacter jejuni and Campylobacter coli to 12 beta-lactam agents and combinations with beta-lactamase inhibitors.
Tajada P; Gomez-Graces JL; Alós JI; Balas D; Cogollos R
Antimicrob Agents Chemother; 1996 Aug; 40(8):1924-5. PubMed ID: 8843305
[TBL] [Abstract][Full Text] [Related]
32. The asparagine to aspartic acid substitution at position 276 of TEM-35 and TEM-36 is involved in the beta-lactamase resistance to clavulanic acid.
Saves I; Burlet-Schiltz O; Swarén P; Lefèvre F; Masson JM; Promé JC; Samama JP
J Biol Chem; 1995 Aug; 270(31):18240-5. PubMed ID: 7629142
[TBL] [Abstract][Full Text] [Related]
33. A piperacillin-tazobactam resistant Escherichia coli strain isolated from a faecal sample of a healthy volunteer.
London N; Thomson CJ; Amyes SG; Stobberingh E
FEMS Immunol Med Microbiol; 1995 Apr; 11(2):107-11. PubMed ID: 7640670
[TBL] [Abstract][Full Text] [Related]
34. Activity of beta-lactamase inhibitor combinations on Escherichia coli isolates exhibiting various patterns of resistance to beta-lactam agents.
Vanjak D; Muller-Serieys C; Picard B; Bergogne-Berezin E; Lambert-Zechovsky N
Eur J Clin Microbiol Infect Dis; 1995 Nov; 14(11):972-8. PubMed ID: 8654448
[TBL] [Abstract][Full Text] [Related]
35. Mechanism of suppression of piperacillin resistance in enterobacteria by tazobactam.
Kadima TA; Weiner JH
Antimicrob Agents Chemother; 1997 Oct; 41(10):2177-83. PubMed ID: 9333044
[TBL] [Abstract][Full Text] [Related]
36. Variants of β-lactamase KPC-2 that are resistant to inhibition by avibactam.
Papp-Wallace KM; Winkler ML; Taracila MA; Bonomo RA
Antimicrob Agents Chemother; 2015 Jul; 59(7):3710-7. PubMed ID: 25666153
[TBL] [Abstract][Full Text] [Related]
37. Structure-function studies of arginine at position 276 in CTX-M beta-lactamases.
Pérez-Llarena FJ; Cartelle M; Mallo S; Beceiro A; Pérez A; Villanueva R; Romero A; Bonnet R; Bou G
J Antimicrob Chemother; 2008 Apr; 61(4):792-7. PubMed ID: 18281307
[TBL] [Abstract][Full Text] [Related]
38. In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains.
Higgins PG; Wisplinghoff H; Stefanik D; Seifert H
Antimicrob Agents Chemother; 2004 May; 48(5):1586-92. PubMed ID: 15105109
[TBL] [Abstract][Full Text] [Related]
39. Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important beta-lactamases.
Payne DJ; Cramp R; Winstanley DJ; Knowles DJ
Antimicrob Agents Chemother; 1994 Apr; 38(4):767-72. PubMed ID: 8031044
[TBL] [Abstract][Full Text] [Related]
40. Ceftazidime and aztreonam resistance in Providencia stuartii: characterization of a natural TEM-derived extended-spectrum beta-lactamase, TEM-60.
Franceschini N; Perilli M; Segatore B; Setacci D; Amicosante G; Mazzariol A; Cornaglia G
Antimicrob Agents Chemother; 1998 Jun; 42(6):1459-62. PubMed ID: 9624494
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
